JPWO2020128870A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020128870A5 JPWO2020128870A5 JP2021534967A JP2021534967A JPWO2020128870A5 JP WO2020128870 A5 JPWO2020128870 A5 JP WO2020128870A5 JP 2021534967 A JP2021534967 A JP 2021534967A JP 2021534967 A JP2021534967 A JP 2021534967A JP WO2020128870 A5 JPWO2020128870 A5 JP WO2020128870A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- antibody
- mixture
- less
- homodimeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 109
- 239000000203 mixture Substances 0.000 claims description 59
- 239000003638 chemical reducing agent Substances 0.000 claims description 34
- 239000000872 buffer Substances 0.000 claims description 20
- 108060003951 Immunoglobulin Proteins 0.000 claims description 18
- 102000018358 immunoglobulin Human genes 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical group NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 16
- 230000003993 interaction Effects 0.000 claims description 15
- 229960003151 mercaptamine Drugs 0.000 claims description 12
- 150000001413 amino acids Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 8
- 230000035772 mutation Effects 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 7
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 7
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 229940072221 immunoglobulins Drugs 0.000 claims description 5
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 4
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 4
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 4
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims description 4
- 229930195710 D‐cysteine Natural products 0.000 claims description 4
- 108010021468 Fc gamma receptor IIA Proteins 0.000 claims description 4
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims description 4
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 4
- 239000004201 L-cysteine Substances 0.000 claims description 4
- 235000013878 L-cysteine Nutrition 0.000 claims description 4
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 4
- 238000011026 diafiltration Methods 0.000 claims description 4
- 229940088679 drug related substance Drugs 0.000 claims description 4
- 102000005962 receptors Human genes 0.000 claims description 4
- 108020003175 receptors Proteins 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 239000007974 sodium acetate buffer Substances 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108010021472 Fc gamma receptor IIB Proteins 0.000 claims description 3
- 108010073807 IgG Receptors Proteins 0.000 claims description 3
- 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 claims description 3
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862781180P | 2018-12-18 | 2018-12-18 | |
| US62/781,180 | 2018-12-18 | ||
| PCT/IB2019/060969 WO2020128870A2 (en) | 2018-12-18 | 2019-12-17 | Methods of producing heterodimeric antibodies |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022513999A JP2022513999A (ja) | 2022-02-09 |
| JPWO2020128870A5 true JPWO2020128870A5 (https=) | 2022-12-21 |
| JP2022513999A5 JP2022513999A5 (https=) | 2022-12-21 |
| JP7645799B2 JP7645799B2 (ja) | 2025-03-14 |
Family
ID=71073358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021534967A Active JP7645799B2 (ja) | 2018-12-18 | 2019-12-17 | ヘテロダイマー抗体の作製方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12415859B2 (https=) |
| EP (1) | EP3897717A4 (https=) |
| JP (1) | JP7645799B2 (https=) |
| KR (1) | KR20210105391A (https=) |
| CN (2) | CN113260380B (https=) |
| BR (1) | BR112021011529A2 (https=) |
| IL (1) | IL284026A (https=) |
| MX (1) | MX2021007119A (https=) |
| SG (1) | SG11202105696QA (https=) |
| TW (1) | TWI874341B (https=) |
| WO (1) | WO2020128870A2 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020022179A2 (pt) | 2018-05-03 | 2021-02-02 | Genmab B.V. | primeiro anticorpo, anticorpo, composição, métodos para tratar um indivíduo tendo uma doença, para esgotar uma população de célula e para induzir a proliferação em uma população de célula, e, kit. |
| CA3176436A1 (en) | 2020-05-08 | 2021-11-11 | Tahamtan Ahmadi | Bispecific antibodies against cd3 and cd20 |
| AU2022206475A1 (en) * | 2021-01-11 | 2023-08-17 | Adimab, Llc | Variant ch3 domains engineered for preferential ch3 heterodimerization, multi-specific antibodies comprising the same, and methods of making thereof |
| KR102828032B1 (ko) * | 2021-09-17 | 2025-07-01 | 고려대학교 산학협력단 | Fc 감마 수용체와의 결합력이 증대된 Fc 변이체 |
| CN116178546B (zh) * | 2022-10-13 | 2024-06-18 | 深圳市百士通科技开发有限公司 | 一种多功能重组抗体及其制备方法和应用 |
| WO2024143442A1 (ja) * | 2022-12-27 | 2024-07-04 | 中外製薬株式会社 | 会合が制御されたポリペプチド |
| AR133071A1 (es) | 2023-06-30 | 2025-08-20 | Genmab As | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ACTIVACIÓN DE FIBROBLASTOS a Y AL RECEPTOR DE MUERTE 4 |
Family Cites Families (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2592668A (en) | 1948-09-08 | 1952-04-15 | Dufour Leon | Locking mechanism for a differential |
| US5292668A (en) | 1981-12-21 | 1994-03-08 | Boston Biomedical Research Institute, Inc. | Bispecific antibody determinants |
| ATE87659T1 (de) | 1986-09-02 | 1993-04-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| SE9201331D0 (sv) | 1992-04-28 | 1992-04-28 | Hightech Receptor C O Active | Protein l och hybridproteiner daerav |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| JP3266276B2 (ja) | 1996-07-25 | 2002-03-18 | ゲーエスエフ―フォルシュングスツェントゥルム・フューア・ウムヴェルト・ウント・ゲズントハイト・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 二重特異性抗体断片の簡易化した製造 |
| US20040038894A1 (en) | 1996-12-31 | 2004-02-26 | Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) | Compounds for modulating cell negative regulations and biological applications thereof |
| JP4213224B2 (ja) | 1997-05-02 | 2009-01-21 | ジェネンテック，インコーポレーテッド | ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法 |
| WO1999055369A1 (en) | 1998-04-28 | 1999-11-04 | Smithkline Beecham Corporation | Monoclonal antibodies with reduced immunogenicity |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| DE19859110A1 (de) | 1998-09-25 | 2000-04-13 | Horst Lindhofer | Bispezifische und trispezifische Antikörper, die spezifisch mit induzierbaren Oberflächenantigenen als operationelle Zielstrukturen reagieren |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ530212A (en) | 2001-06-13 | 2006-09-29 | Genmab As | An isolated human monoclonal antibody that binds to human epidermal growth factor receptor (EGFR) |
| CN101928344B (zh) | 2002-10-17 | 2014-08-13 | 根马布股份公司 | 抗cd20的人单克隆抗体 |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| JP2006524039A (ja) | 2003-01-09 | 2006-10-26 | マクロジェニクス，インコーポレーテッド | 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法 |
| CA2529945A1 (en) | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| US20060134105A1 (en) | 2004-10-21 | 2006-06-22 | Xencor, Inc. | IgG immunoglobulin variants with optimized effector function |
| AU2003280713A1 (en) | 2003-11-04 | 2005-05-19 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibody |
| US20050136051A1 (en) | 2003-12-22 | 2005-06-23 | Bernard Scallon | Methods for generating multimeric molecules |
| US8772013B2 (en) | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US20050208519A1 (en) | 2004-03-12 | 2005-09-22 | Genenews Inc. | Biomarkers for diagnosing schizophrenia and bipolar disorder |
| US7537930B2 (en) | 2004-07-23 | 2009-05-26 | Immunomedics, Inc. | Mammalian cell lines for increasing longevity and protein yield from a cell culture |
| US20060074225A1 (en) | 2004-09-14 | 2006-04-06 | Xencor, Inc. | Monomeric immunoglobulin Fc domains |
| US8911726B2 (en) | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
| JP5553963B2 (ja) | 2004-10-22 | 2014-07-23 | アムジエン・インコーポレーテツド | 組換え抗体をリフォールディングする方法 |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| WO2007103112A2 (en) | 2006-03-03 | 2007-09-13 | Elan Pharmaceuticals, Inc. | Methods of treating inflammatory and autoimmune diseases with natalizumab |
| US8871912B2 (en) | 2006-03-24 | 2014-10-28 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| GB0621513D0 (en) | 2006-10-30 | 2006-12-06 | Domantis Ltd | Novel polypeptides and uses thereof |
| WO2008119353A1 (en) | 2007-03-29 | 2008-10-09 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2144628B1 (en) | 2007-05-08 | 2012-10-17 | Genentech, Inc. | Cysteine engineered anti-muc16 antibodies and antibody drug conjugates |
| AU2008255352B2 (en) | 2007-05-31 | 2014-05-22 | Genmab A/S | Stable IgG4 antibodies |
| AU2008255350B2 (en) | 2007-05-31 | 2014-07-10 | Genmab A/S | Transgenic animals producing monovalent human antibodies and antibodies obtainable from these animals |
| UA107557C2 (xx) | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| WO2009023562A2 (en) | 2007-08-09 | 2009-02-19 | Wyeth | Use of perfusion to enhance production of fed-batch cell culture in bioreactors |
| JP2011507519A (ja) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | ｐＩＸ又はｐＶＩＩへの融合を介したヒトデノボｐＩＸファージディスプレイライブラリの設計及び作製、ベクター、抗体、及び方法 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| ES2563027T3 (es) | 2008-01-07 | 2016-03-10 | Amgen Inc. | Método para fabricación de moléculas heterodímeras Fc de anticuerpos utilizando efectos de conducción electrostática |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| JP5746040B2 (ja) | 2008-12-03 | 2015-07-08 | ゲンマブ エー／エス | 定常領域の中に改変を有する抗体変種 |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| CN102946906B (zh) | 2010-04-23 | 2015-07-15 | 弗·哈夫曼-拉罗切有限公司 | 生产异源多聚体蛋白质 |
| US9527926B2 (en) | 2010-05-14 | 2016-12-27 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| CA2808154A1 (en) | 2010-08-13 | 2012-02-16 | Medimmmune Limited | Monomeric polypeptides comprising variant fc regions and methods of use |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| WO2012104344A1 (en) | 2011-02-01 | 2012-08-09 | Genmab A/S | Human antibodies and antibody-drug conjugates against cd74 |
| AU2012222833B2 (en) | 2011-03-03 | 2017-03-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design and constructs |
| US10239952B2 (en) | 2011-04-01 | 2019-03-26 | Memorial Sloan Kettering Cancer Center | Anti-WT1/HLA bi-specific antibody |
| JP6177231B2 (ja) | 2011-04-20 | 2017-08-09 | ゲンマブ エー／エス | Ｈｅｒ２に対する二重特異性抗体 |
| US20140170148A1 (en) | 2011-04-20 | 2014-06-19 | Genmab A/S | Bispecific antibodies against her2 |
| CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| EP2768857B1 (en) | 2011-10-19 | 2020-01-01 | NovImmune SA | Methods of purifying antibodies |
| US10344050B2 (en) * | 2011-10-27 | 2019-07-09 | Genmab A/S | Production of heterodimeric proteins |
| CA2854233C (en) | 2011-11-04 | 2020-05-12 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the fc domain |
| LT2794905T (lt) | 2011-12-20 | 2020-07-10 | Medimmune, Llc | Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams |
| PT2825559T (pt) | 2012-03-13 | 2019-06-07 | Novimmune Sa | Anticorpos biespecíficos prontamente isolados com formato de imunoglobulina nativo |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| US9062120B2 (en) | 2012-05-02 | 2015-06-23 | Janssen Biotech, Inc. | Binding proteins having tethered light chains |
| BR112015000167B1 (pt) | 2012-07-06 | 2021-11-23 | Genmab B.V. | Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante |
| ES2758979T3 (es) | 2012-07-06 | 2020-05-07 | Genmab Bv | Proteína dimérica con mutaciones triples |
| US20170275367A1 (en) * | 2012-11-21 | 2017-09-28 | Janssen Biotech, Inc. | Bispecific EGFR/C-Met Antibodies |
| CN113201073A (zh) | 2012-11-21 | 2021-08-03 | 詹森生物科技公司 | 双特异性EGFR/c-Met抗体 |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| LT2953969T (lt) * | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui |
| KR102216003B1 (ko) | 2013-03-15 | 2021-02-16 | 얀센 바이오테크 인코포레이티드 | 재조합 단백질에서 c-말단 라이신, 갈락토스 및 시알산 함량을 제어하기 위한 제조 방법 |
| JP6586016B2 (ja) | 2013-03-15 | 2019-10-02 | ノヴォ ノルディスク アー／エス | 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 |
| US9595164B2 (en) | 2013-05-16 | 2017-03-14 | Bally Gaming, Inc. | Social gaming website and related in-advertisement gaming |
| JO3568B1 (ar) | 2014-09-05 | 2020-07-05 | Janssen Pharmaceutica Nv | عوامل ربط cd123 واستخداماتها |
| CN104301917A (zh) | 2014-09-15 | 2015-01-21 | 浙江生辉照明有限公司 | 基于照明装置的网络异常自愈方法及系统 |
| DK3233907T3 (da) | 2014-12-19 | 2021-06-07 | Genmab As | Bispecifikke heterodimeriske proteiner hos gnavere |
| JP6247241B2 (ja) | 2015-02-27 | 2017-12-13 | ノバルティス アーゲー | 抗体処方 |
| ES2973885T3 (es) | 2015-07-09 | 2024-06-24 | Genmab As | Anticuerpos biespecíficos y multiespecíficos y método para aislarlos |
| CN109071658A (zh) | 2016-02-05 | 2018-12-21 | 根马布股份公司 | 具有改进的内化特性的多特异性抗原-结合分子 |
| KR102329490B1 (ko) * | 2016-09-14 | 2021-11-23 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Ｉｌ-１７ａ에 특이적으로 결합하는 항체 및 그의 기능성 단편 |
| ES2897217T3 (es) | 2016-09-30 | 2022-02-28 | Hoffmann La Roche | Anticuerpos biespecíficos frente a p95HER2 |
| KR20250140128A (ko) | 2017-02-10 | 2025-09-24 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| EP3743440A1 (en) | 2018-01-24 | 2020-12-02 | Genmab B.V. | Polypeptide variants and uses thereof |
| CN112513074A (zh) | 2018-06-22 | 2021-03-16 | 健玛保 | 生产两种或更多种不同抗体的受控混合物的方法 |
-
2019
- 2019-12-16 TW TW108145933A patent/TWI874341B/zh active
- 2019-12-17 SG SG11202105696QA patent/SG11202105696QA/en unknown
- 2019-12-17 BR BR112021011529A patent/BR112021011529A2/pt unknown
- 2019-12-17 CN CN201980084454.2A patent/CN113260380B/zh active Active
- 2019-12-17 WO PCT/IB2019/060969 patent/WO2020128870A2/en not_active Ceased
- 2019-12-17 CN CN202511974952.8A patent/CN121914277A/zh active Pending
- 2019-12-17 JP JP2021534967A patent/JP7645799B2/ja active Active
- 2019-12-17 KR KR1020217022128A patent/KR20210105391A/ko active Pending
- 2019-12-17 US US16/717,189 patent/US12415859B2/en active Active
- 2019-12-17 MX MX2021007119A patent/MX2021007119A/es unknown
- 2019-12-17 EP EP19899975.7A patent/EP3897717A4/en active Pending
-
2021
- 2021-06-15 IL IL284026A patent/IL284026A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522266A5 (https=) | ||
| JP7178342B2 (ja) | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のＦｃドメイン含有分子 | |
| US12180279B2 (en) | Method for in vivo generation of multispecific antibodies from monospecific antibodies | |
| JP7450535B2 (ja) | 単一特異性抗体から多重特異性抗体を生成させるための方法 | |
| CN102471378B (zh) | 容易地分离的具有天然免疫球蛋白形式的双特异性抗体 | |
| JP2022544760A (ja) | 改善された単鎖可変断片のための材料及び方法 | |
| RU2019108429A (ru) | Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения | |
| JP7645799B2 (ja) | ヘテロダイマー抗体の作製方法 | |
| US20220112288A1 (en) | Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii | |
| JPWO2021030657A5 (https=) | ||
| JP2021511298A5 (https=) | ||
| JPWO2020128870A5 (https=) | ||
| JPWO2021019389A5 (https=) | ||
| RU2021121021A (ru) | Способы получения гетеродимерных антител | |
| JPWO2019140273A5 (https=) | ||
| JPWO2023026235A5 (https=) | ||
| JPWO2022047243A5 (https=) | ||
| US20260055171A1 (en) | Vegf antagonists and methods of use thereof | |
| JPWO2023156409A5 (https=) | ||
| JP2022545368A (ja) | ４－１ｂｂおよび０ｘ４０結合タンパク質ならびに関連する組成物および方法、４－１ｂｂに対する抗体、０ｘ４０に対する抗体 | |
| US20260092123A1 (en) | ENGINEERED IgG MOLECULES AND METHODS OF USE THEREOF | |
| WO2021150266A1 (en) | Agents that interfere with il-1beta receptor signalling | |
| JPWO2023023465A5 (https=) | ||
| Brezski | Novel Generation of Antibody-Based Therapeutics | |
| RU2025109063A (ru) | Мутанты антител свиных |